SERUM VALUES OF SEROTONIN UNDER AN IMPACT OF PERINDOPRIL AND CANDESARTAN IN WHITE LABORATORY RAT WITH INDUCED DIABETIC NEPHROPATHY
Keywords:
Diabetic nephropathy, serum, serotonin, perindopril, candesartanAbstract
While many previous studies on the localization and function of tissue or local RAS have focused on their pathophysiological relevance, many new aspects of the physiological role of these systems are still undiscovered. The previous clinical extensive research of angiotensin converting enzyme inhibitors (ACEi) and angiotensin AT1 receptor antagonists (ARBs) as antihypertensive agents provided a numerous examples of enigmatic experiences in improving of hypertension at diabetic nephropathy (DN). This research aims to determine the impact of ACEi, Perindopril and ARBs AT1, Candesartan, singly and in combination on the level of serotonin in the serum at Wistar rats with diabetic nephropathy induced with Streptozotocin (STZ). The Serotonin levels in the serum were measured with enzyme-linked immunosorbent assay (ELISA), on four experimental groups: control group with DN, group with DN + Perindopril, group with DN + Candesartan and the DN group in combination with Perindopril + Candesartan. Perindopril (6 mg/Kg/day), Candesartan (5mg/Kg/day) and dual therapy with Perindopril (3mg/Kg/day) and Candesartan (2,5mg/Kg/day) was administered peroraly every day during 8 weeks, starting after 4 weeks from administration of STZ, while the control group received water alone. At the end of treatment the rats were sacrificed so the serum was taken for the measurement of Serotonin levels. The results demonstrate that in all groups, the blockade of renin – angiotensin system (RAS), with Perindopril, Candesartan and their combination significantly decrease the level of Serotonin in the serum.
References
Berger, M., Gray, J.A., & Roth, B.L. (2009). “The expended biology of serotonin”. Annu. Rev. Med. 60: 355-366.
Blount, M.A., Sands, J.M., Kent, K.J., Smith, T.D., Price, S.R. & Klein, J.D. (2008). “Candesartan augments compensatory change in medullary transport proteins in the diabetic rat kidney”. Am J Physiol Renal Physiol. 294(6): F1448-52.
Burnier, M., Lin, Sh., Ruilope L., Bader, G., Durg, Sh., & Brunel, P. (2019). Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. Blood Pressure, 28:6, 358-374
Deacon, C.F. (2020). “Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes,” Peptides, vol. 100, pp. 150–157
Furman, B. L. (2021). Streptozotocin-Induced Diabetic Models in Mice and Rats. https://doi.org/10.1002/cpz1.78
Hernandez, L.L. (2018). ADSA Foundation Scholar Award: A role for serotonin in lactation physiology—Where do we go from here? Journal of Dairy Science Vol. 101 No. 7
Hodzic E., Pecar, E., DzuburA., Smajic, E., Hondo, Z., Delic, D. & Rustempasic, E. (2020). Efficacy and Safety of Perindopril in Patients with Essential Hypertension. Mater Sociomed; 32(1): 4-9
Hsu, F.Y., Lin, F.J., Ou, H.T., Huang, S.H. & Wang, C.C. (2017). Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria. Kidney Blood Press Res; 42:358–368
Lammel-Lindemann, J.A., Flores-Villalba, E., Martagon, A.J., DeObeso-Gonzalez,E. & Puente-Gallegos, F. (2018). “Non cholestatic acute hepatocellular injury following candesartan administration,” British Journal of Clinical Pharmacology, vol. 84, no. 1, pp. 204–207
Leoncini, G., Viazzi, F., De Cosmo, S., Russo, G., Fioretto, P., & Pontremoli, R. (2020). Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. Journal of Nephrology vol. 33: 949–963.
Paul, M., Mehr, A.P., & Kreutz, R. (2006). “Physiology of Local Renin-Angiotensin Systems”. Physiol Rev 86: 747-803.
Rieder, M., Laumann, R., Witsch T., Schanze N., Heger L., Olivier C. B., von zur Muehlen C., Bode, C., Ahrens, I., Lother, A., Duerschmied, D. & Hortmann, M. (2020). Evaluation of Serum Serotonin as a Biomarker for Myocardial Infarction and Ischemia/Reperfusion Injury. Appl. Sci. 10, 6379
Rossini, A. A., Like, A. A., Chick, W. L., Appel, M. C., & Cahill Jr, G. F. (1977). "Studies of streptozotocin-induced insulitis and diabetes". Proceedings of the National Academy of Sciences of the United States of America 74 (6): 2485–2489.
Ruiz-Ortega, M., Rodrigues-Diez, R. R., Lavoz, C. & Rayego-Mateos S. (2020). Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”. Ј Clin. Med. 9, 813;
Vavra, J. J., Deboer, C., Dietz, A., Hanka, L.J. & Sokolski, W.T. (1959). "Streptozotocin, a new antibacterial antibiotic". Antibiot Annu 7: 230–5.
